최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Pharmaceutical fronts : Chinese journal of pharmaceutical b, v.3 no.3, 2021년, pp.e129 - e137
Liu, Fei (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Liu, Xi-Zi (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Yang, Qian (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Han, Shi-Yi (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Fan, Si-Yang (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China)
Simultaneous oral intake of herbal medicine with chemical drugs may result in beneficial pharmacodynamic efficacy, including additive and synergistic effects with reduced toxicity. Gnaphalium affine D. Don (GAD) is a traditional Chinese Medicine that has been used for the management of hyperuricemia...
D Chen Chinese herbal medicines facilitate the control of chemotherapy-induced side effects in colorectal cancer: progress and perspective Front Pharmacol 2018 10.3389/fphar.2018.01442 9 1442
W Wang The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis Phytomedicine 2020 10.1016/j.phymed.2019.153136 68 153136
X Luo The add-on effect of Chinese herbal medicine on COVID-19: a systematic review and meta-analysis Phytomedicine 2021 10.1016/j.phymed.2020.153282 85 153282
F Liu Hypouricemic activity of Gnaphalium affine D. Don [in Chinese] Shenyang Yaoke Daxue Xuebao 2020 01 37 12
W Zhang Chemical constituents from Gnaphalium affine and their xanthine oxidase inhibitory activity Chin J Nat Med 2018 05 16 347
H J Zhang Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis J Ethnopharmacol 2017 10.1016/j.jep.2017.03.057 203 304
C Li Extraction and purification of total flavonoids from Gnaphalium affine D. Don and their evaluation for free radicals' scavenging and oxidative damage inhabitation potential in mice liver Arab J Chem 2021 10.1016/j.arabjc.2021.103006 03 14 103006
L Jiang Protective effect of Gnaphalium tranzscelii against acute liver injury in mice [in Chinese] Shizhen Guo Yi Guo Yao 2008 08 19 1901
Chinese Society of Endocrinology CMA Guideline for the diagnosis and management of hyperuricemia and gout in China (2019) [in Chinese] Zhonghua Neifenmi Daixie Zazhi 2020 01 36 1
M H Lee A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008 10.2165/00002018-200831080-00002 08 31 643
W Parzefall Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver Toxicol Appl Pharmacol 1990 10.1016/0041-008X(90)90343-S 03 106 482
P Sun Benzbromarone aggravates hepatic steatosis in obese individuals Biochim Biophys Acta Mol Basis Dis 2018 10.1016/j.bbadis.2018.03.009 1864 2067
N Liu EGF receptor inhibition alleviates hyperuricemic nephropathy J Am Soc Nephrol 2015 10.1681/ASN.2014080793 11 26 2716
X Liu HPLC method for determination of uric acid in plasma of hyperuricemia model mice [in Chinese] Yaowu Pingjia Yanjiu 2017 03 40 319
T Dai Quantitative analysis in drug combination (author's transl) [in Chinese] Zhongguo Yaolixue Tongbao 1998 05 14 479
D Hoffmann Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity Toxicology 2010 10.1016/j.tox.2010.08.013 277 49
C Mende Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy Adv Ther 2015 10.1007/s12325-015-0272-7 12 32 1177
L Strilchuk Safety and tolerability of available urate-lowering drugs: a critical review Expert Opin Drug Saf 2019 10.1080/14740338.2019.1594771 04 18 261
P Richette Gout Lancet 2010 10.1016/S0140-6736(09)60883-7 375 318
L Billiet Review of hyperuricemia as new marker for metabolic syndrome ISRN Rheumatol 2014 10.1155/2014/852954 2014 852954
A Takemura Inhibition of biliary network reconstruction by benzbromarone delays recovery from pre-existing liver injury Toxicology 2019 10.1016/j.tox.2019.05.004 423 32
F Zhang Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy Food Chem Toxicol 2021 10.1016/j.fct.2021.111998 149 111998
F Zhang Herb-drug interaction between Styrax and warfarin: molecular basis and mechanism Phytomedicine 2020 10.1016/j.phymed.2020.153287 77 153287
K Kobayashi Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes Biopharm Drug Dispos 2012 10.1002/bdd.1813 08 33 466
M Yoshida Association of a reactive intermediate derived from 1′,6-dihydroxy metabolite with benzbromarone-induced hepatotoxicity J Biochem Mol Toxicol 2017 10.1002/jbt.21946 10 31 e21946
Y Kimura Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity Food Chem Toxicol 2010 10.1016/j.fct.2009.10.041 01 48 429
H Rastogi Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome p450 activities Phytother Res 2014 10.1002/ptr.5220 12 28 1873
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.